Status: Recruiting
A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer
The primary objective of this study is to compare the overall survival (OS) and progression-free survival (PFS) between MRG002 and investigator selected chemotherapy in patients with HER2-positive unresectable locally advanced or metastatic urothelial cancer previously treated with platinum-based chemotherapy and PD-1/PD-L1 inhibitors.
Participants needed: 290
Trial details
Phase: Phase 3Age: 18-75Biological sex: AllType: InterventionalSponsor: Shanghai Miracogen Inc.Updated: Apr 13, 2023Locations: 1
Eligibility criteria
1. Willing to sign the ICF and follow the requirements specified in the protocol...
1. History of hypersensitivity to any component of MRG002 or history of hypersen...